来曲唑在子宫内膜异位症手术后的应用分析

摘要

Objective To observe endometriosis surgery using letrozole therapy.Methods 122 patients with endometriosis were randomly divided into two groups, the observation group(n=61 cases) and the control group(n=61 cases). They were treated through operation first. The patients in the observation group were treated through GnRH-a, while the patients in the control group were treated through letrozole. They were treated for six months. Serum CA125 were detected before and after treatment.Results The total effective rates were 82.0% in the control group and 85.2% in the observation group. There was not a significantly different between two groups(χ2=2.24,P>0.05). Serum CA125 in the control group before and after treatment were (41.6±7.4) μg/L and (21.5±4.6) μg/L respectively. Serum CA125 in the observation group before and after treatment were (40.8±6.8) μg/L and (11.5±3.7) μg/L respectively. Serum CA125 in the two groups after treatment were significantly lowered (t = 3.7708, 6.9018,P<0.01), compared with the control group after treatment, observation group reduced more obviously after treatment (t=2.9016,P<2.9016). The control group, 20 cases occurred adverse reactions during treatment, the rate was 32.8%.The observation group had eight cases of adverse reactions, the rate was 13.1%.Adverse reaction rates in the observation group was significantly less than the control group (χ2 =4.98, P<0.05).Conclusions Letrozole and GnRH - a had the same effectiveness after surgery, letrozole after treatment the prognosis is better, but less adverse reaction.%目的：观察子宫内膜异位症手术后采用来曲唑治疗的效果。方法122例子宫内膜异位症患者按照数字表法随机分为两组，对照组61例，观察组61例，两组均采用手术治疗。对照组手术后采用促性腺激素释放激素激动剂（GnRH-a）治疗，观察组术后采用来曲唑治疗，两组共治疗6个月。治疗后评价疗效及血清糖类抗原CA125（CA125）的变化。结果对照组总有效率为82.0%，观察组总疗效为85.2%；两组总有效率无明显差异（χ2=2.24，P>0.05）。对照组治疗前后血清CA125分别为（41.6±7.4）μg/L和（21.5±4.6）μg/L；观察组治疗前后血清CA125分别为（40.8±6.8）和（11.5±3.7）μg/L。两组血清CA125在治疗后均有明显降低（t=3.7708、6.9018，P<0.01），与对照组治疗后比较，观察组治疗后降低更明显（t=2.9016，P<0.05）。对照组治疗期间有20例发生不良反应，发生率为32.8%；观察组有8例发生不良反应，发生率为13.1%；观察组不良反应发生率明显少于对照组（χ2=4.98，P<0.05）。结论子宫内膜异位症手术后采用来曲唑和GnRH-a疗效相当，但来曲唑治疗后预后更好，不良反应更少。